APA (7th ed.) Citation

Aldred, J., Freire-Alvarez, E., Amelin, A. V., Antonini, A., Bergmans, B., Bergquist, F., . . . Talapala, S. (2023). Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study. Neurology & Therapy, 12(6), 1937. https://doi.org/10.1007/s40120-023-00533-1

Chicago Style (17th ed.) Citation

Aldred, Jason, et al. "Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study." Neurology & Therapy 12, no. 6 (2023): 1937. https://doi.org/10.1007/s40120-023-00533-1.

MLA (9th ed.) Citation

Aldred, Jason, et al. "Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study." Neurology & Therapy, vol. 12, no. 6, 2023, p. 1937, https://doi.org/10.1007/s40120-023-00533-1.